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Gastrointestinal stromal tumors (GIST) can be molecularly classified based on different subtypes including
mutations in KIT and PDGFRA. Patients with PDGFRA mutations are an important subgroup that com-
monly arise in the stomach and are associated with a more indolent disease course. Importantly, the most
common PDGFRA molecular subtype, the D842V mutation in exon 18 of the gene which alters the ac-
tivation loop, is imatinib insensitive in in vitro studies. Poor responses to imatinib have been seen clini-
cally compared with PDGFRA exon 18 non-D842V-mutated GIST. Avapritinib (BLU-285) is a potent KIT and
PDGFRA-specific tyrosine kinase inhibitor which has shown >90% response rates in patients with PDGFRA
exon 18 D842V-mutated GIST. Results from the Phase I trial of avapritinib have indicated that this drug
should be the standard of care for patients with PDGFRA exon 18 D842V-mutated GIST.
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Gastrointestinal stromal tumors (GIST) can occur anywhere within the digestive tract, though are most commonly
found in the stomach and small intestine. GIST are the most common mesenchymal tumor of the gastrointestinal
(GI) tract and their cell of origin is thought to be related to the interstitial cells of Cajal [1].
The molecular subtype of GIST is both prognostic and predictive, and molecular testing is considered standard
of care for patients undergoing systemic therapy [2]. The majority, around 95% [3], of GIST are positive for c-KIT
(CD117) by immunohistochemistry [4]. Around 70–80% of these patients have a c-KIT mutation which leads
to constitutional kinase activation [3]. The most common mutations affect the juxtamembrane domain of exon
11 (61–71%) causing ligand-independent activation [3,5]. PDGFRA mutations represent the oncogenic molecular
alteration in 28–35% of non-KIT-mutated GIST and are mutually exclusive of c-KIT mutations [3,6–8]. Specifically,
the frequency of patients with activating PDGFRA mutations in Phase III clinical trials is 1.6–2.7% [9], whereas in
population studies the incidence is between 7.9 and 14% [9,10]. This may be due to the higher rates of relapse-free
survival seen in patients with PDGFRA mutations [9]. The most common PDGFRA mutation is exon 18 D842V [8]
followed by other mutations in exon 18, exon 12, exon 14 and exon 4 [3,11]. Non-KIT/PDGFRA-mutated GIST
subtypes include NF1-related, PI3KCA, mutations deficiencies in the succinate dehydrogenase complex, BRAF
mutant and quadruple wild-type (succinate dehydrogenase, KIT, PDGFRA and NF1 proficient) [5].
For patients with localized GIST, surgery followed by either surveillance (low-to-intermediate risk) or adjuvant
imatinib (high risk) GIST is a standard of care [2,12]. Patients with GIST are risk stratified based on size, location
and mitotic rate [13]. For patients who present with metastatic disease, systemic therapy with the tyrosine kinase
inhibitor (TKI) imatinib is a standard first-line treatment [2]. However, within the relatively uncommon PDGFRA
molecular subtype, there is a growing body of literature demonstrating differential responses to imatinib in patients
with PDGFRA exon 18 D842V mutations and nonexon 18 D842V mutations [10,14,15].
This Review will address the treatment of patients with PDGFRA exon 18 mutations in the context of the
development of the TKI avapritinib.
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PDGFRA mechanism of oncogenesis
KIT and PDGFRA belong to the same sub-family of Type III receptor tyrosine kinases which transmit downstream
signals via JAK/STAT, Ras/ERK, PI3K and AKT pathways [3]. Although the downstream signaling pathways of
KIT and PDGFRA mutant GIST were thought to be similar, gene expression profiling has shown that each class
of mutations display differential expression of downstream signaling pathways. In an analysis of 26 GIST, there
were higher levels of AKT/PI3K pathway genes in KIT-mutated GIST, while higher levels of genes associated
with T-cell receptor signaling were seen in PDGFRA-mutated GIST [16]. Whereas, a similar study of 22 GIST
suggested variations in expression of 70 genes between PDGFRA- and KIT-mutated GIST [17]. Though further
work is required to fully understand the clinical implications of differential gene expression, it has become clear that
an important clinical distinction for some subgroups of patients with PDGFRA mutations is a lack of sensitivity to
TKI therapy.
The most common mutation is a single nucleotide substitution 2664A→T leading to D842V activating muta-
tion [18]. This mutation results in distortion of the kinase activation loop causing an altered protein conformation
which favors the active structure. This leads to imatinib insensitivity in D842V mutants as imatinib can only bind
to the inactive form of PDGFRA [5].
The second most common activating substitution is on exon 12, 1821T→A causing the V561D mutation.
Other rare mutations including substitutions, deletions, duplications and insertions have been reported that are
physically close to exon 18 D842V or exon 12 V561D, however, due to their very low incidence, little is known
about the specific behavior of these mutations.
Others are physically close to D842V including D842Y, D842I, D846Y, Y849C and D845Y [18].
PDGFRA clinicopathological characteristics
Patients with PDGFRA mutations are predominantly male (58.3–70%), with the majority of patients (91–95%)
having a gastric primary [8,9,15,19]. More patients have epithelioid or mixed histological subtypes compared with
KIT mutants which tend to display a spindle cell morphology [19]. This morphological difference may be due to
downstream activation of proteins involved in actin reorganization [20].
Patients with PDGFRA mutations have a spectrum of clinical presentations, from benign to malignant [8]. Early
studies identified their association with more indolent and low risk disease [8,15,21]. More contemporary retrospective
studies have also suggested that PDGFRA mutant GIST are significantly more often very low/low risk compared
with KIT mutants (49 vs 26%), more often had tumors in the stomach (91 vs 45%) and more frequently (70
vs 42%) had <5 mitoses per 50 high power field compared with KIT mutant GIST [9]. Within this cohort, low
mitotic rate and gastric primary correlated with significant increases in the 5-year recurrence-free survival [9].
In a large European retrospective cohort across 12 institutions, PDGFRA mutations were found in 11%
(382/3510) patients, with only a small proportion (12.5%, 44/365) of these patients having metastatic dis-
ease [11]. In a separate large study of 1056 patients with localized GIST who underwent surgery, included 148
patients with PDGFRA mutations (13.6%). Patients with tumors harboring PDGFRA mutations had a significantly
better disease-free survival compared with those with tumors harboring KIT exon 9 and 11 mutations (median
disease-free survival, not reached vs 45.5 months, respectively). There was no difference in outcome when PDGFRA
D842V mutants were compared with all other PDGFRA mutants [22].
PDGFRA mutations – therapeutic implications
In vitro data have suggested that imatinib response differs between PDGFRA mutants. Nearly all exon 18 D842
mutants (apart from D842Y) have been shown to be imatinib resistant [10,14]. Whereas other PDGFRA mutants
have been found to be imatinib sensitive [10,14], which should be interpreted with caution given the overall small
sample size. However, this in vitro finding of differential sensitivity dependent on PDGFRA mutation has also been
reported in patient cohorts [15].
Neoadjuvant/metastatic disease
Data regarding imatinib use in this relatively uncommon subset of GIST are limited. In a retrospective analysis
of the large Phase III trials of first-line imatinib [14], there was no difference found in progression-free survival
(PFS), overal survival (OS) or response rate (RR) for patients with exon 11, 9 or KIT/PDGFRA wild-type GIST
at imatinib 400 or 800 mg dosage. It should be noted, however, that 15.9% of patients were KIT/ PDGFRA
wild-type, and in total only 1.1% of patients had tumors with PDGFRA mutations. Thus, it is difficult to be certain
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if there is a differential benefit to imatinib treatment for patients given the rarity of PDGFRA mutations in patients
in these trials [14].
Evidence from retrospective cohorts of PDGFRA mutant GIST supports differential imatinib sensitivity between
differentPDGFRAmutations. In a European retrospective study, patients with non-PDGFRAD842V mutations had
improved response with imatinib compared with those with D842V mutations (D842V progressive disease = 68%
vs non-D842V = 12%) [11]. There was a statistically significant difference in PFS between patients with tumors with
D842V mutations versus other non-D842V exon 18 mutations (2.8 vs 28.5 months, respectively) on imatinib. The
OS was poorer for patients with D842V mutations (14.7 months vs not reached for non-D842V mutations) [11].
Patients with D842V mutations, who had PFS greater than 6 months on imatinib had lower mitotic counts, which
may suggest more indolent variants of disease rather than true imatinib effect [11].
In a recent Dutch–American registry study of a cohort of patients with PDGFRA D842V-mutated GIST,
neoadjuvant or palliative intent imatinib resulted in progressive disease for the majority of patients (10/17,
58.9%), with median time to progression of 8 months. Interestingly, the clinical benefit rate was 29.4%, with
11.8% of patients (2/17) showing partial response to imatinib [15]. Consistent with preclinical data [10,14], 100%
(8/8) of patients with non-D842V mutations had clinical benefit from imatinib (75% partial response [PR], 25%
stable disease [SD]) [15]. The biological mechanism proposed by the authors is multiple GIST clones existing within
a patient, with some harboring imatinib sensitive mutations. These results illustrate that even with in vitro data
suggesting resistance, clinically there may be some rationale in the use of imatinib at some point for patients with
D842V mutations in the absence of a clinical trial [15], novel TKIs or exhausting all other lines of therapy.
Adjuvant imatinib
Given small numbers of patients with PDGFRA mutations in the Z9001 trial (4.6–6% of patients had PDGFRA
D842V mutations), benefit of adjuvant imatinib based on retrospective subgroup analysis was not possible [23].
While type ofKITmutation was shown in an exploratory analysis to impact patient outcome for the SSGXVIII/AIO
randomized trial, there was no difference for patients with PDGFRA mutations [24]. However, analysis was likely
limited by the relatively small proportion of patients with PDGFRA mutations (12.6%).
A Dutch–American retrospective cohort study, found that all of the 3/11 patients with localized disease treated
with adjuvant imatinib remained recurrence-free at 23 months [15]. However, given retrospective data showing
improved disease free survival (DFS) and overall low risk features of patients with PDGFRA, these results may
simply be due to the fact that patients with PDGFRA overall have a better prognosis, and/or have a more indolent
disease course and/or late metastasis [8,15,21].
Treatment with TKIs beyond imatinib
While patients with non-D842V mutations have been shown to benefit from imatinib treatment, limited data
exist regarding the benefit of further TKI use within this population given the limited number of patients with
exon 18 mutations enrolled on clinical trials and grouping of PDGFRA into KIT/ PDGFRA wild-type GIST [25].
Long-term disease stability in one patient with a PDGFRA exon 18 D842V mutation from a small cohort (n = 20)
of patients with metastatic GIST on regorafenib has been reported [26]. Instead, within this specific population,
focus has shifted to prioritize these patients for enrollment on clinical trials of novel agents.
Development of avapritinib (BLU-285)
Given the in vitro and clinical data indicating imatinib resistance within the D842V mutant patient population,
there has been a recognition of the therapeutic need for potent PDGFRA exon 18 D842V inhibitors. In addition,
the PDGFRA D842V structural analog mutation on the KIT gene (D816V) is involved in the pathogenesis of
systemic mastocytosis, which also represents a condition with limited therapeutic options. This recognition led
to the rational identification of BLU-285, now known as avapritinib [27]. In vitro, avapritinib was selected due to
its specificity for KIT activation loop mutations and PDGFRA mutants. Specifically, its half maximal inhibitory
concentration (IC50) is over 3000-times less than imatinib against PDGFRA exon 18 D842V mutants [27]. This
activity has been confirmed in GIST xenografts, where avapritinib showed dose-dependent decrease in tumor
volume for exon 11, exon 11/17 and exon 9 KIT mutant xenografts [28]. Notably, in imatinib resistant cell lines
(exon11/17 line), avapritinib inhibited tumor progression significantly better than regorafenib [28].
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Based on this initial in vitro activity, the Phase I NAVIGATOR study was opened in 2015 for patients with
advanced GIST who had been treated with at least two lines of TKI or advanced disease with the D842V
mutation [29].
Initial results were presented at the American Society of Clinical Oncology 2017 [30]. The dose escalation
component of NAVIGATOR has been completed with the maximum tolerated dose 400 mg po daily. For the
25 patients with exon 18 D842V-mutated GIST, tumor regression was seen across all dose levels (30-400 mg
orally daily) [30]. Disease control rate was an impressive 100% using either RECIST 1.1 or Choi criteria (Choi:
25/25 PR vs RECIST 1.1 15/25 PR, 10/25) based on central radiological review. The median PFS was not
reached for this cohort. Reported common adverse events were nausea (60%, grade 1–43%), fatigue (53%, grade
1–22%) and vomiting (42%, grade 1–29%). Dose limiting toxicities were hyperbilirubinemia, rash, hypertension
and memory impairment [30].
Updated results presented at the Connective Tissue Oncology Society 2018 [31] including 231 patients, out of
which 56 (24%) had exon 18 D842V-mutated GIST, continued to demonstrate efficacy within this population [31].
The overall response rate (ORR) was 84% (47/56), with 9% (5/56) complete response (CR), 75% PR (42/56)
giving a clinical benefit rate of 96% (54/56) by central review per RECIST 1.1. Final results of the NAVIGATOR
study are required to confirm these impressive results. With greater numbers of patients and longer follow-up,
memory impairment was documented in 26% (60/231) of patients, with the majority of these patients experiencing
grade 1 impairment (19%–45/231). No grade 5 adverse events were reported. The response rate in KIT mutant
GIST was lower, with ORR 26% (PR: 6/23–26%, CR: 0/23) for patients in 3L/4L regorafenib naive GIST, and a
lower response rate for patients treated with ≥4 lines of TKI (ORR: 20%, PR: 21/109–19%, CR: 1/109–1%) [31].
However, it is encouraging that these initial response rates are higher than those for current standard of care options
sunitinib (second line, RR = 7% [32]) or regorafenib (third line, RR = 4.5% [33]). Notably, a placebo-controlled
Phase III trial, INVICTUS, of the novel TKI ripretinib in the fourth line and beyond setting of metastatic GIST
also showed promise in this heavily pretreated group [34]. The response rate for ripretinib versus placebo was 9.4
and 0%, respectively, with the PFS 6.3 versus 1 month, respectively. In vitro activity suggests that, while both novel
TKIs are more potent than imatinib, avapritinib is more potent than ripretinib for D842V mutations [35]. However,
it remains to be seen whether ripretinib will have clinical activity against PDGFRA exon D842V mutations.
The NAVIGATOR dose expansion has enrolled two cohorts, PDGFRA D842V mutant, and unresectable GIST
after imatinib and ≥2 previous TKI [31]. Given the American Society of Clinical Oncology [30] and the Connective
Tissue Oncology Society [31] presentations congruent with respect to efficacy, the final results of the Phase I trial [36]
have shown an impressive ORR and PFS with avapritinib for patients with PDGFRA exon 18 D842V mutations.
The cognitive effects represent an important adverse event as they are an unfamiliar side effect compared with other
TKIs used in oncology. It is important to explore alternative contributing causes. Early recognition is important,
as in the majority of cases memory impairment is manageable with a dose delay and reduction [37]. In addition, the
five most common adverse events reported were nausea (61%, 46% was grade 1), fatigue (55%, 21% was grade 1,
28% was grade 2), anemia (46%, 25% was grade 3), periorbital edema (40%, 34% grade 1) and diarrhea (39%,
22% was grade 1) [31]. These adverse events are familiar to clinicians as they do have similarity to other commonly
used TKIs. In total, 8.7% of patients discontinued avapritinib due to any adverse event.
Based on priority review of preliminary data from the Phase I trial [30,31], on 9 January 2020, the US FDA approved
avapritinib for patients with unresectable or metastatic GIST with PDGFRA exon 18 D842V mutation with
breakthrough therapy designation [38]. This represents the first approved therapy for patients with PDGFRA exon
18 D842V mutations [38].
Current clinical practice: patients with PDGFRA exon 18 mutations
Given PDGFRA exon 18 mutations are relatively uncommon subtype of GIST patients, it is still important to
consider such patients for enrollment on clinical trials.
Neo/adjuvant therapy
For patients with localized GIST with molecular confirmation of a PDGFRA exon 18 D842V mutation and
upfront resectable disease, resection is recommended. If a patient has locally advanced, unresectable disease,
given the impressive response rates, clinicians should strongly consider neoadjuvant avapritinib with the aim of
downstaging the tumor to enable complete resection. There is currently no evidence for the use of avapritinib in
the adjuvant setting for patients with resected disease. Given the known imatinib insensitivity [10,14], guidelines
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recommend against adjuvant therapy with imatinib for patients with tumors harboring D842V mutations [2].
However, in patients with known imatinib sensitive PDGFRA mutations, if the patient meets criteria for adjuvant
imatinib, this should be offered.
Advanced disease
Based on the preliminary Phase I results from NAVIGATOR [39], in the absence of clinical trials, clinicians should
attempt to gain access to avapritinib for their patients with D842V mutations.
For patients with PDGFRA exon 18 D842V mutations without access to avapritinib, upfront surveillance could
be considered for patients with localized disease given their indolent clinical behavior. For symptomatic patients,
local therapy including embolization, ablation [40] and even potentially surgery could be considered based on expert
consensus. Metastatic disease can behave aggressively and treatment is very challenging without effective systemic
therapy. Informed use of standard of care TKIs can be cautiously considered within this patient population.
However, based on the preliminary results of the NAVIGATOR study, avapritinib is the current international
standard of care for PDGFRA exon 18 D842V mutations. We would advocate for availability of avapritinib for all
patients with PDGFRA exon 18 D842V-mutated GIST.
For patients with PDGFRA exon 18 non-D842V mutations, these have generally been found to be sensitive
to imatinib [11,15]. Until there is further comparative data for imatinib and avapritinib, first-line imatinib is
recommended in this patient population.
Conclusion
Patients with tumors harboring PDGFRA exon 18 mutations are a relatively rare but important molecular subgroup
of GIST. Though PDGFRA exon 18 mutations are associated with more indolent disease in the localized setting,
differential response to imatinib exists between subtypes. Non-D842V mutations are generally imatinib sensitive
and this has correlated to a better outcome for these patients. However, though small retrospective cohorts indicate
very modest benefit (at best) with imatinib in patients with tumors harboring the D842V mutation, they often
have a short PFS and standard of care TKIs provide limited benefit. Avapritinib is a novel TKI identified with
specificity for PDGFRA and KIT mutations. Preclinical data have demonstrated impressive inhibition of both KIT
and PDGFRA including difficult-to-treat KIT D816V and its analogous PDGFRA exon 18 D842V mutation. Early
results of the Phase I NAVIGATOR trial demonstrate notable ORR and clinical benefit rate (CBR) in patients with
advanced PDGFRA exon 18 D842V-mutated GIST with manageable toxicities. Final results of the Phase I and
Phase III VOYAGER study are eagerly awaited to confirm outcomes within the difficult-to-treat D842V cohort
and establish avapritinib as the new standard of care for patients with D842V-mutated GIST.
Future perspective
Based on the promising preliminary Phase I results, the Phase III VOYAGER study was opened in March 2018 and
has completed enrollment. Patients with advanced GIST who have received imatinib and one or two other TKIs
are randomized to regorafenib or avapritinib 300 mg po daily [39]. Crossover is allowed upon progression, which
may limit OS analysis. The primary end point is PFS based on RECIST 1.1 and secondary end points include
OS, ORR and quality of life. For the population pretreated with 2–3 TKIs, the larger sample size and randomized
design will be key to better understand the activity of avapritinib in this cohort and observe adverse events of
this novel agent over a larger population [36]. A press release by Blueprint Medicines on 28 April 2020 revealed
median PFS of 4.2 and 5.6 months for avapritinib (n = 240) and regorafenib (n = 236), respectively, which was not
statistically significant [41]. Interestingly, ORR was higher in the avapritinib-treated patients (17.1% for avapritinib
vs 7.2% for regorafenib), with no new safety signals observed [41]. Full results are needed to understand why the
difference in response rate did not translate to a PFS benefit, and if specific subgroups may benefit. Clinicians have
more experience with regorafenib dose titration compared with avapritinib, and this may have contributed to the
regorafenib PFS being slightly higher in VOYAGER (5.6 vs 4.8 months) than observed in the initial Phase III trial
of regorafenib for advanced GIST [33].
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Executive summary
• Gastrointestinal stromal tumors (GIST) are most commonly found in the stomach and small intestine are the most
common mesenchymal tumor found in the gastrointestinal tract.
• Molecular subtype of GIST has important predictive and prognostic implications.
• PDGFRA mutations represented a small but important subgroup of GIST.
• The most common PDGFRA mutation is exon 18 D842V.
Therapeutic implications of PDGFRA mutations
• Patients are more often male, with gastric primaries and epithelioid or mixed histological subtypes.
• Retrospectively, patients have been shown to generally have more indolent disease compared with patients with
KIT mutations.
• In vitro and clinical studies have demonstrated PDGFRA D842V mutations conferring resistance to imatinib, while
other non-D842V mutations are generally imatinib sensitive.
Role of novel tyrosine kinase inhibitor, avapritinib
• Avapritinib is a potent PDGFRA exon 18 D842V tyrosine kinase inhibitor and has been approved by the US FDA
for patients with PDGFRA D842V mutant GIST as of 9 January 2020.
• The final results from the Phase I NAVIGATOR and Phase III VOYAGER (avapritinib vs regorafenib) are awaited to
confirm the initial results in the PDGFRA exon 18 D842V population.
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